PT - JOURNAL ARTICLE AU - Jonathan P Rogers AU - Cameron Watson AU - James Badenoch AU - Benjamin Cross AU - Matthew Butler AU - Jia Song AU - Danish Hafeez AU - Hamilton Morrin AU - Emma Rachel Rengasamy AU - Lucretia Thomas AU - Silviya Ralovska AU - Abigail Smakowski AU - Ritika Dilip Sundaram AU - Camille Kaitlyn Hunt AU - Mao Fong Lim AU - Daruj Aniwattanapong AU - Vanshika Singh AU - Zain Hussain AU - Stuti Chakraborty AU - Ella Burchill AU - Katrin Jansen AU - Heinz Holling AU - Dean Walton AU - Thomas A Pollak AU - Mark Ellul AU - Ivan Koychev AU - Tom Solomon AU - Benedict Daniel Michael AU - Timothy R Nicholson AU - Alasdair G Rooney TI - The neurology and neuropsychiatry of COVID-19: a systematic review and meta-analysis of the early literature reveals frequent CNS manifestations and key emerging narratives AID - 10.1101/2021.02.24.21252335 DP - 2021 Jan 01 TA - medRxiv PG - 2021.02.24.21252335 4099 - http://medrxiv.org/content/early/2021/02/26/2021.02.24.21252335.short 4100 - http://medrxiv.org/content/early/2021/02/26/2021.02.24.21252335.full AB - Objectives There is accumulating evidence of the neurological and neuropsychiatric features of infection with SARS-CoV-2. In this systematic review and meta-analysis, we aimed to describe the characteristics of the early literature and estimate point prevalences for neurological and neuropsychiatric manifestations.Methods We searched MEDLINE, Embase, PsycInfo and CINAHL up to 18 July 2020 for randomised controlled trials, cohort studies, case-control studies, cross-sectional studies and case series. Studies reporting prevalences of neurological or neuropsychiatric symptoms were synthesised into meta-analyses to estimate pooled prevalence.Results 13,292 records were screened by at least two authors to identify 215 included studies, of which there were 37 cohort studies, 15 case-control studies, 80 cross-sectional studies and 83 case series from 30 countries. 147 studies were included in the meta-analysis. The symptoms with the highest prevalence were anosmia (43.1% [35.2—51.3], n=15,975, 63 studies), weakness (40.0% [27.9—53.5], n=221, 3 studies), fatigue (37.8% [31.6—44.4], n=21,101, 67 studies), dysgeusia (37.2% [30.0—45.3], n=13,686, 52 studies), myalgia (25.1% [19.8—31.3], n=66.268, 76 studies), depression (23.0 % [11.8—40.2], n=43,128, 10 studies), headache (20.7% [95% CI 16.1—26.1], n=64,613, 84 studies), anxiety (15.9% [5.6—37.7], n=42,566, 9 studies) and altered mental status (8.2% [4.4—14.8], n=49,326, 19 studies). Heterogeneity for most clinical manifestations was high.Conclusions Neurological and neuropsychiatric symptoms of COVID-19 in the pandemic’s early phase are varied and common. The neurological and psychiatric academic communities should develop systems to facilitate high-quality methodologies, including more rapid examination of the longitudinal course of neuropsychiatric complications of newly emerging diseases and their relationship to neuroimaging and inflammatory biomarkers.Competing Interest Statement- Jonathan Rogers has received payment by the Alberta Psychiatric Association for a lecture and has held one unpaid advisory meeting with representatives from Promentis Pharmaceuticals Inc regarding drug development. - Lucretia Thomas is in receipt of a bursary as part of the Royal College of Psychiatrists PsychStar scheme. By winning a prize from the Royal College of Psychiatrists, she has received prize money and free attendance at a meeting. She is President of the University of Birmingham Psychiatry Society. - Ivan Koychev has been supported by the Medical Research Council through Dementias Platform UK and by the National Institute for Health Research through the Oxford Health Biomedical Research Centre. He has been a medical advisor to Mantrah Ltd and Sharp Therapeutics Ltd, digital technology start-ups. He holds stock options in Sharp Therapeutics Ltd. - Tom Solomon is supported by the National Institute for Health Research (NIHR) Health Protection Research Unit in Emerging and Zoonotic Infections (Grant Nos. IS-HPU-1112-10117 and NIHR200907), NIHR Programme Grant for Applied Research (No. RP-PG-0108-10,048), NIHR Global Health Research Group on Brain Infections (No. 17/63/110), and the European Union's Horizon 2020 research and innovation program ZikaPLAN (Preparedness Latin America Network), grant agreement No. 734584. He receives royalties from Oxford University Press, Elsevier, Liverpool University Press and Cambridge University Press. He is a consultant for the MHRA Vaccine Benefit Risk Expert Working Group. He filed for a patent on a test for bacterial meningitis based on a blood test (No. GB1606537.7 14th April 2016). He was on the Data Safety Monitoring Committee of the GSK Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children GSK3390107A (ChAd3 EBO-Z) vaccine. He chaired the Siemens Healthineers Clinical Advisory Board (1) Data safety monitoring board: Study of Ebola vaccine ChAd3-EBO-Z - Commercial entity. He holds shares in Medefer Solutions. - Benedict Michael has received payment for a lecture for Valneva. - All other authors declare no competing interests. Clinical Protocols https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=200768 Funding StatementJPR is supported by a Wellcome Trust Clinical Training Fellowship (102186/B/13/Z). MB is an NIHR Academic Clinical Fellow (ACF-2019-17-008). HH is supported by the Deutsche Forschungsgemeinschaft (German Research Foundation) (HO1286/16-1). TP is supported by a National Institute of Health Research (NIHR) Clinical Lectureship. ME is supported by the Association of British Neurologists through a Clinical Research Training Fellowship. ME and TS are supported by the NIHR Health Protection Research Unit in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England, in collaboration with Liverpool School of Tropical Medicine and the University of Oxford (NIHR200907). IK is supported by the Medical Research Council (Dementias Platform UK Grant MR/L023784/2) and the Oxford Health Biomedical Research Centre. DA is supported by the Faculty of Medicine, Chulalongkorn University, Thailand. AGR is supported by the Royal College of Physicians of Edinburgh, John, Margaret, Alfred and Stewart Sim Fellowship 2018-2020. BDM is supported by the UKRI/MRC COVID-CNS Grant (MR/V03605X/1), the MRC-CSF (MR/V007181/1), and the MRC/AMED grant (MR/T028750/1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Secondary research (systematic review), so exempt from ethical review.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available to interested parties following reasonable request to the first author.